Sepehr Golriz Khatami

Dr. Sepehr Golriz Khatami

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
SKSepehr Golriz Khatami
Sepehr Golriz Khatami
SMSarah Mubeen
Sarah Mubeen
VBVinay Srinivas Bharadhwaj
Vinay Srinivas Bharadhwaj
AKAlpha Tom Kodamullil
Alpha Tom Kodamullil
MHMartin Hofmann-Apitius
Martin Hofmann-Apitius
DDDaniel Domingo
Daniel Domingo
The utility of pathway signatures lies in their capability to determine whether a specific pathway or biological process is dysregulated in a given patient. These signatures have been widely used in machine learning (ML) methods for a variety of applications including precision medicine, drug repurposing, and drug discovery. In this work, we leverage highly predictive ML models for drug response simulation in individual patients by calibrating the pathway activity scores of disease samples. Using these ML models and an intuitive scoring algorithm to modify the signatures of patients, we evaluate whether a given sample that was formerly classified as diseased, could be predicted as normal following drug treatment simulation. We then use this technique as a proxy for the identification of potential drug candidates. Furthermore, we demonstrate the ability of our methodology to successfully identify approved and clinically investigated drugs for four different cancers, outperforming six comparable state-of-the-art methods. We also show how this approach can deconvolute a drugs’ mechanism of action and propose combination therapies. Taken together, our methodology could be promising to support clinical decision-making in personalized medicine by simulating a drugs’ effect on a given patient.

23 March 2021 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
SKSepehr Golriz Khatami
Sepehr Golriz Khatami
DDDaniel Domingo-Fernández
Daniel Domingo-Fernández
SMSarah Mubeen
Sarah Mubeen
CHCharles Tapley Hoyt
Charles Tapley Hoyt
CRChristine Robinson
Christine Robinson
MHMartin Hofmann-Apitius
Martin Hofmann-Apitius
Background: Neuroimaging markers provide quantitative insight into brain structure and function in neurodegenerative diseases, such as Alzheimer’s disease, where we lack mechanistic insights to explain pathophysiology. These mechanisms are often mediated by genes and genetic variations and are often studied through the lens of genome-wide association studies. Linking these two disparate layers (i.e., imaging and genetic variation) through causal relationships between biological entities involved in the disease’s etiology would pave the way to large-scale mechanistic reasoning and interpretation. Objective: We explore how genetic variants may lead to functional alterations of intermediate molecular traits, which can further impact neuroimaging hallmarks over a series of biological processes across multiple scales. Methods: We present an approach in which knowledge pertaining to single nucleotide polymorphisms and imaging readouts is extracted from the literature, encoded in Biological Expression Language, and used in a novel workflow to assist in the functional interpretation of SNPs in a clinical context. Results: We demonstrate our approach in a case scenario which proposes KANSL1 as a candidate gene that accounts for the clinically reported correlation between the incidence of the genetic variants and hippocampal atrophy. We find that the workflow prioritizes multiple mechanisms reported in the literature through which KANSL1 may have an impact on hippocampal atrophy such as through the dysregulation of cell proliferation, synaptic plasticity, and metabolic processes. Conclusion: We have presented an approach that enables pinpointing relevant genetic variants as well as investigating their functional role in biological processes spanning across several, diverse biological scales.

19 April 2022 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
SKSepehr Golriz Khatami
Sepehr Golriz Khatami
YSYasamin Salimi
Yasamin Salimi
MHMartin Hofmann-Apitius
Martin Hofmann-Apitius
NONeil P. Oxtoby
Neil P. Oxtoby
CBColin Birkenbihl
Colin Birkenbihl
TIthe Alzheimer’s Disease Repository Without Borders Investigators
the Alzheimer’s Disease Repository Without Borders Investigators
Background Previous models of Alzheimer's disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies. However, cohort datasets are subject to specific inclusion and exclusion criteria that influence the signals observed in their collected data. Furthermore, each study measures only a subset of AD-relevant variables. To gain a comprehensive understanding of AD progression, the heterogeneity and robustness of estimated progression patterns must be understood, and complementary information contained in cohort datasets be leveraged. Methods We compared ten event-based models that we fit to ten independent AD cohort datasets. Additionally, we designed and applied a novel rank aggregation algorithm that combines partially overlapping, individual event sequences into a meta-sequence containing the complementary information from each cohort. Results We observed overall consistency across the ten event-based model sequences (average pairwise Kendall's tau correlation coefficient of 0.69 +/- 0.28), despite variance in the positioning of mainly imaging variables. The changes described in the aggregated meta-sequence are broadly consistent with the current understanding of AD progression, starting with cerebrospinal fluid amyloid beta, followed by tauopathy, memory impairment, FDG-PET, and ultimately brain deterioration and impairment of visual memory. Conclusion Overall, the event-based models demonstrated similar and robust disease cascades across independent AD cohorts. Aggregation of data-driven results can combine complementary strengths and information of patient-level datasets. Accordingly, the derived meta-sequence draws a more complete picture of AD pathology compared to models relying on single cohorts.

29 January 2024 in Data
Verified
Journal Article
Open access
PDF file
SKSepehr Golriz Khatami
Sepehr Golriz Khatami
ASAstghik Sargsyan
Astghik Sargsyan
MRMaria Francesca Russo
Maria Francesca Russo
DDDaniel Domingo
Daniel Domingo
AZAndrea Zaliani
Andrea Zaliani
AKAlpha Tom Kodamullil
Alpha Tom Kodamullil
Although hundreds of datasets have been published since the beginning of the coronavirus pandemic, there is a lack of centralized resources where these datasets are listed and harmonized to facilitate their applicability and uptake by predictive modeling approaches. Firstly, such a centralized resource provides information about data owners to researchers who are searching datasets to develop their predictive models. Secondly, the harmonization of the datasets supports simultaneously taking advantage of several similar datasets. This, in turn, does not only ease the imperative external validation of data-driven models but can also be used for virtual cohort generation, which helps to overcome data sharing impediments. Here, we present that the COVID-19 data catalogue is a repository that provides a landscape view of COVID-19 studies and datasets as a putative source to enable researchers to develop personalized COVID-19 predictive risk models. The COVID-19 data catalogue currently contains over 400 studies and their relevant information collected from a wide range of global sources such as global initiatives, clinical trial repositories, publications, and data repositories. Further, the curated content stored in this data catalogue is complemented by a web application, providing visualizations of these studies, including their references, relevant information such as measured variables, and the geographical locations of where these studies were performed. This resource is one of the first to capture, organize, and store studies, datasets, and metadata related to COVID-19 in a comprehensive repository. We believe that our work will facilitate future research and development of personalized predictive risk models for COVID-19.

29 September 2026 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
SKSepehr Golriz Khatami
Sepehr Golriz Khatami
RBRieke Baumkötter
Rieke Baumkötter
TKThomas Köck
Thomas Köck
AAAyesha Syed Mamoor Alam
Ayesha Syed Mamoor Alam
JCJulian Chalabi
Julian Chalabi
PWPhilipp S. Wild
Philipp S. Wild

15 November 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SKSepehr Golriz Khatami
Sepehr Golriz Khatami
MRMaria Francesca Russo
Maria Francesca Russo
DDDaniel Domingo
Daniel Domingo
AZAndrea Zaliani
Andrea Zaliani
SMSarah Mubeen
Sarah Mubeen
AKAlpha Tom Kodamullil
Alpha Tom Kodamullil
The COVID-19 data catalogue is a repository that provides a landscape view of COVID-19 studies and datasets as a putative source to enable researchers to develop personalized COVID-19 predictive risk models. The COVID-19 data catalogue currently contains over 400 studies and their relevant information collected from a wide range of global sources such as global initiatives, clinical trial repositories, publications and data repositories. Further, the curated content stored in this data catalogue is complemented by a web application, providing visualizations of these studies, including their references, relevant information such as measured variables, and the geographical locations of where these studies were performed. This resource is one of the first to capture, organize and store studies, datasets and metadata in the area of COVID-19 in a comprehensive repository. We are convinced that our work will facilitate future research and development of personalized predictive risk models of COVID-19.